Pharmacologically targeting TAK1, the serine/threonine protein kinase that is functionally implicated in the regulation of SASP development, should reduce the SASP and prevent tumor cells from acquiring resistance factors from damaged stromal cells in the TME, resulting in significant tumor regression.320. Here, AKT1 is linked to neoplasm.